在三阴性乳腺癌中耐药性持久细胞的表征确定了跨治疗和患者的共享持久性计划
Léa Baudre1, Gregoire Jouault2, Pacôme Prompsy3
1Institute Curie, Paris, France.
Cancer research
|November 6, 2025
概括
耐药性持久细胞驱动抗癌疗法耐药性. 这些细胞表现出可塑性,并在复发时恢复到一个天真的状态,其中关键驱动因素包括AP-1,NF-κB和IRF/STAT,为新疗法提供了点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 获得抗癌疗法耐药性是由耐药性持久细胞驱动的.
- 患者中持久细胞的有限可获得性阻碍了对其出现机制的理解.
- 持久细胞对于治疗失败和癌症复发至关重要.
研究的目的:
- 为了研究活体转录性可塑性,持久性细胞.
- 确定三阴性乳腺癌 (TNBC) 和其他癌症中持续状态的特征和关键驱动因素.
- 探索FOSL1在建立持久状态中的作用.
主要方法:
- 利用患者衍生的模型来隔离和研究持久细胞.
- 分析了转录特征和基因调控网络.
- 研究了FOSL1在持续细胞形成中的功能作用.
主要成果:
- 持久性细胞在体内表现出转录性可塑性,在复发时恢复到先前未接受治疗的状态.
- 在TNBC中持续状态的标志包括高基底蛋白表达和激活的压力/炎症通路,也在其他癌症类型中观察到.
- AP-1,NF-κB和IRF/STAT被确定为关键驱动因素,其中FOSL1 (AP-1成员) 功能性地将细胞驱动到持久状态.
结论:
- 该研究定义了跨疗法TNBC持久性的标志.
- 在建立持久状态方面,FOSL1起着至关重要的作用.
- 这些发现为设计结合疗法以克服抗药性提供了资源.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Stem Cells and Tumor Maintenance
5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


